Sentences with phrase «follicular lymphoma patients»

The combination of rituximab (Rituxan) and the novel immunotherapy pidilizumab (CT - 011) is both active and well tolerated in follicular lymphoma patients, according to results of a phase II trial presented by Jason R. Westin, MD, of the MD Anderson Cancer Center in Houston, at the American Society of Hematology (ASH) meeting in Atlanta.

The combination improved upon the 40 % overall response rate seen for monotherapy rituximab treatment in relapsed follicular lymphoma patients.

Data from 29 patients from the single - arm trial in relapsed follicular lymphoma patients showed a 66 % (19 patients) overall response rate — 15 patients were complete responses and 4 patients were partial responses.

The lab of Elisa Oricchio at EPFL, with colleagues from the US and Canada, analyzed the genomes of over 200 follicular lymphoma patients.

Moreover, approximately 30 % of follicular lymphoma patients lose also a portion of chromosome 6, affecting multiple genes involved in suppressing the emergence of a tumor.

Not exact matches

Dose - densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high - risk diffuse large B - cell / follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Groulymphoma patients: results of a phase II Nordic Lymphoma GrouLymphoma Group study.

Exon - Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B - Cell / Follicular Grade 3 Lymphoma Patients Treated with Dose - Dense Chemoimmuno - therapy and CNS Prophylaxis.

The FDA granted approval to rituximab and hyaluronidase (Rituxan Hycela) for patients with follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).

The FDA granted approval to obinutuzumab (GAZYVA), a targeted antibody against CD20, for patients with follicular lymphoma.

Current treatment options for patients, aside from watchful waiting, include chemotherapy and rituximab, which was approved for first - line follicular lymphoma in 2006.

«The impressive and durable response of the single patient with follicular lymphoma on the phase I trial of this agent spoke to its potential in this disease,» Westin added.

Pfizer's rituximab investigational biosimilar PF - 05280586 met the primary endpoint of overall response rate equivalence to rituximab - EU (MabThera) as a frontline treatment for patients diagnosed with CD20 - positive follicular lymphoma, the company announced.

Positron emission tomography (PET) imaging of metabolic tumor burden at diagnosis and after induction therapy can help identify patients most at risk of follicular lymphoma (FL) recurrence, but more work is needed to differentiate high - risk and moderate - risk patients, suggested findings from a pooled analysis of data from three prospective clinical trials, published in Blood.

Status: G100 is being studied in a fully - enrolled randomized Phase 2 trial in patients with follicular non-Hodgkin Lymphoma (FL) in combination with local radiation and Merck's anti-PD-1 agent, pembrolizumab, pursuant to a clinical collaboration with Merck.

«Both total metabolic tumor volume (TMTV), computed on baseline PET, and end - of - induction PET (EOI PET) are imaging biomarkers showing promise for early risk stratification in patients with high tumor - burden follicular lymphoma,» reported lead author Anne Ségolène Cottereau, MD, from Cochin Hospital, René Descartes University, Paris, France, and colleagues.

These patients had either chemorefractory DLBCL or variants of DLBCL like primary mediastinal B - cell lymphoma or transformed follicular lymphoma.

Risk - stratification tools are needed to identify which patients face the highest risk of recurrence, but the existing Follicular Lymphoma International Prognostic Index (FLIPI) and FLIPI2 prognostic calculators do not reliably identify these patients.